(RTTNews.com) – Bio-pharmaceutical company Horizon Pharma plc Friday said it would acquire Crealta Holdings LLC for $510 million in cash, expanding its Orphan business, with the addition of KRYSTEXXA, the first and only FDA-approved medicine for chronic refractory gout.
The deal is expected to add $70 million – $80 million in net sales and $45 million – $50 million in adjusted EBITDA for Horizon, in the first twelve months, upon completion.
The acquisition, which is likely to close in the first quarter 2016 and approved by the boards of both companies, is subject to the satisfaction of customary closing conditions and regulatory approvals, including antitrust approval in the United States.
Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.
Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.
The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).
